Provenienza dei contatti di primo grado di Nadine Brew
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Brandon Capital Partners Pty Ltd.
Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.
7
| Private Company | Investment Managers | 7 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Nadine Brew tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Investment Managers | Corporate Officer/Principal | |
TOUCHSTONE INNOVATIONS PLC | Investment Managers | Corporate Officer/Principal | |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor | |
University of Oxford | College/University | Undergraduate Degree | |
Imperial College London | College/University | Masters Business Admin | |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Graduate Degree | |
University College London | College/University | Doctorate Degree Doctorate Degree | |
RMIT University | College/University | Undergraduate Degree | |
Swinburne University of Technology | College/University | Graduate Degree | |
Molecular Vision Ltd.
Molecular Vision Ltd. Medical SpecialtiesHealth Technology Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom. | Medical Specialties | Director/Board Member | |
Elastagen Pty Ltd.
Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Medical Specialties | Chief Executive Officer | |
Australian Graduate School of Entrepreneurship | College/University | Graduate Degree | |
ABINGDON HEALTH PLC | Medical Specialties | Private Equity Investor | |
The University of Auckland Business School | College/University | Graduate Degree | |
ARIX BIOSCIENCE PLC | Investment Managers | Chief Executive Officer | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Autism Research Trust
Autism Research Trust Medical/Nursing ServicesHealth Services Autism Research Trust provides health care services. The private company is based in Leeds, UK. The CEO of the British company is Marie Davies. | Medical/Nursing Services | Director/Board Member | |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Myricx Pharma Ltd.
Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
NRG Therapeutics Ltd.
NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Miscellaneous Commercial Services | Director/Board Member | |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
Regno Unito | 16 |
Stati Uniti | 5 |
Australia | 5 |
Israele | 3 |
Nuova-Zelanda | 2 |
Settori
Health Technology | 12 |
Consumer Services | 9 |
Finance | 5 |
Commercial Services | 5 |
Health Services | 2 |
Posizioni
Director/Board Member | 15 |
Private Equity Investor | 6 |
Graduate Degree | 4 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 3 |
Contatti più connessi
Insiders | |
---|---|
Jonathan Leslie Tobin | 19 |
Robert Daniels | 6 |
Robin Carr | 4 |
Matthew Sandalis | 3 |
Rana Ali | 2 |
Prashanth Rajan | 1 |
Christina Kulis | 1 |
- Borsa valori
- Insiders
- Nadine Brew
- Connessioni Società